The pharmacology of memory

Comptes Rendus de l'Academie des Sciences - Serie III

Volumn 321, Issue 2-3, 1998, Pages 209-215

  Iversen, Susan D ^a  

^a Department of Experimental Psychology ^*  (United Kingdom)

Author keywords

Emotional memory; Long term memory; Neurotransmitters; Working memory

Indexed keywords

ACETYLCHOLINE; CHOLINERGIC RECEPTOR STIMULATING AGENT; DOPAMINE; MUSCARINIC AGENT; NEUROTRANSMITTER; PHYSOSTIGMINE; SCOPOLAMINE;

ALZHEIMER DISEASE; COGNITIVE DEFECT; EMOTION; HUMAN; MEMORY; MONKEY; NONHUMAN; PREFRONTAL CORTEX; REVIEW; SUBSTITUTION THERAPY; WORKING MEMORY;

EID: 0032005093     PISSN: 07644469     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0764-4469(97)89824-1     Document Type: Article

References (27)

1. Dawson G.R., Heyes C.M., Iversen S.D. 1992. Pharmacological mechanisms and animal models of cognition. Behav. Pharmacol. 3,285-297.
2. Bakin J.S., VVeinberger N.M. 1996. Induction of a physiological memory in the cerebral cortex by stimulation of the nucleus basalis. Proc. NatJ. Acad. Sei. 93, 11219-11224.
3. Drachman D.A. 1977. Memory and cognitive function in man: Does the cholinergic system have a specific role? Neurology 27, 783-790.
4. Dunnett S.B., Everitt B.J., Robbins T.W. 1991. The basal forebraincortical cholinergic system: interpreting the functional consequences of excitotoxic lesions. TINS 14, 494-501.
5. Iversen S.D. 1997. Behaviour evaluation of cholinergic drugs. Life Sei. 60,1145-1152.
6. Davvson G.R., Iversen S.D. 1993. The effects of novel cholinesterase inhibitors and selective muscarinic receptor agonists in tests of reference and working memory. Behav. Brain Res. 57, 143-153.
7. Davvson G.R., Bayley P., Channell S., Iversen S.D. 1993. A comparison of the effects of novel muscarinic receptor agonists L-689, 660 and AF 102 B in tests of long term and working memory. Psychopharmacology 113,361-368.
8. Rupniak N.M.)., Tye S.)., Iversen S.D. 1992. Comparison of the effects of selective and non-selective muscarinic agonists on cognition and thermo-régulation in primates. J. Neurol. Sei. 110, 222-227.
9. Davvson G.R., Bentley G., Draper F., Rycroft W., Iversen S.D., Pagella P.C. 1991. The behavioural effects of heptyl physostigmine, a new cholinesterase inhibitor, in tests of long term and working memory in rodents. Pharm. Biochem. Behav. 39, 865-871.
10. Rupniak N.M.)., Field M.J., Samson N.A., Steventon M.)., Iversen S.D. 1990. Direct comparison of cognitive facilitation by physostigmine and tetrahydroaminoacridine in two primate models. Neurobiol. Ageing 11,609-613.
11. Matsuoka N., AignerT.G. 1997. FK960 [N-4-Acetyl-1 -piperazinyl) - p-fluoroben zamide Monohydrate], a novel potential anti-dementia drug, improves visual recognition memory in Rhesus monkeys: comparison with physiostigmine. J. Pharm. Exp. Ther. 280, 1201-1209.
12. Fox N.C., Freeborough P.A., Rossor M.N. 1996. Visualisation and quantification of rates of atrophy in Alzheimer's disease. Lancet 348, 9497.
13. Johnson-Wood K., Lee M., Motter R., Hu K., Gordon G., Barbour R., Khan K., Gordon M., Tan H., Games D., Lieberburg I., Schenk D., Seubert P., McConlogue L. 1997. Amyloid precursor protein processing and A42 deposition in a transgenic mouse model of Alzheimer disease. Proc. A/atJ. Acad. Sd. 94, 1550-1555.
14. London C.L., Ashall F., Coate A.M. 1997. Exploring the etiology of Alzheimer Disease using molecular genetics. / Am. Med. Assoc. 277, 825-831.
15. Lindsay R.M. 1995. Neuron saving schemes. Nature 373, 289-290.
16. Scott S.A., Mufson E.J., Weingartner I.A., Skau K.A., Crutcher K.A. 1995. Nerve growth factor in Alzheimer's disease: Increased levels throughout the brain coupled with declines in nucleus basalis. J. NeuroseJ. 15, 6213-6221.
17. Berger B., Caspar P., Verney C. 1991. Dopaminergic innervation of the cerebral cortex: unexpected differences between rodents and primates. TINS 14, 21-27.
18. Brozoski T., Brown R.M., Rosvold H.E., Goldman P.S. 1979. Cognitive deficit caused by regional depletion of dopamine in prefrontal cortex of rhesus monkey. Science 205, 929-932.
19. Sawaguchi T., Coldman-Rakic P.S. 1991. D1 dopamine receptors in prefrontal cortex: involvement in working memory. Science 251, 947950.
20. Williams C.V., Goldman-Rakic P.S. 1995. Modulation of memory fields by dopamine D1 receptors in prefrontal cortex. Nature 376, 572-575.
21. Desimone R. 1995. Is dopamine a missing link? Nature 549-550.
22. Floresco S.B., Seamans J.K., Phillips A.C. 1997. Selective roles for hippocampal, prefrontal cortical, and ventral striatal circuits in radial-arm maze tasks with or without a delay. J. NeuroseJ. 17, 1880-1890.
23. Mrzljak L, Bergson C., Pappy M., Huff R., Levenson R., ColdmanRakic P.S. 1996. Localisation of dopamine D4 receptors in GABAergic neurons of the primate brain. Na(ure381, 245-247.
24. Iversen S.D. 1995. Interactions between excitatory amino acids and dopamine systems in the fo/ebrain. Implications for Schizophrenia and Parkinson's disease. Behav. Pharmacol. 6, 478-491.
25. Dolan R.J., Fletcher P., Frith C.D., Friston K.J., Frackowiak R.S.J., Grasby P.M. 1995. Dopaminergic modulation of impaired cognitive activation in the anterior cingulate cortex in schizophrenia. Nature 378, 180-182.
26. McGaughJ.L., Cahill L. and Roozendaal B. 1996. Involvement of the amygdala in memory storage: interactions with other brain systems. Proc. NatJ. Acad. Sei. 93, 13508-13514.
27. Cahill L., Prins B., Weber M., McCaugh J.L. 1994. -adrenergic activation and memory for emotional events. Nature (London) 371, 702704.